Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Companies find their products are best

Executive Summary

Industry-sponsored head-to-head statin trials are 20 times more likely to favor the sponsor's drug than a comparator, an article in the June issue of the Public Library of Science states. In an evaluation of 192 randomized controlled trials, Lisa Bero, University of California-San Francisco, et al., also finds that company-sponsored trials are 35 times more likely to reach a conclusion in favor of the sponsor's product. Antipsychotic trials have been found to be similarly biased (1"The Pink Sheet" Feb. 6, 2006, p. 9)...

You may also be interested in...

Antipsychotic Trials Biased Towards Sponsor’s Drug, Study Suggests

Clinical trial protocols for head-to-head comparisons of antipsychotic drugs should be reviewed by regulatory authorities like FDA to eliminate potential sources of bias, according to a recent analysis published in the American Journal of Psychiatry

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts